Destiny Pharma PLC - clinical stage biotechnology company based in Brighton - Says Brazil's Industrial Property Office issues a notice of allowance that will lead to the final approval in March of the company's patent application for XF-73, a nasal gel that prevents post-surgical infections.
"We are very pleased to obtain this additional patent award PI 0512563-4. We now have 84 issued patents from three patent families related to our XF platform that will provide strong protection to our XF-73 nasal gel product, alongside standard market exclusivity awards, in all major territories," says Chief Executive Neil Clarke.
In January, Destiny Pharma completed enrolment in its Phase 2b clinical trial testing of XF-73. It expects to release full results of the study towards the end of March 2021 after which it will plan the Phase 3 clinical programme.
Current stock price: 122.00 pence, up 6.1% on Wednesday
Year-to-date change: up 78%
By Ife Taiwo; ifetaiwo@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Destiny Pharma. (DEST)